|
|
Upfront Briefing
Monday brings a Korean peptide, a congressional letter, and a PDUFA date that quietly walked past without saying anything. Genentech put $190M down for Hanmi’s HM17321 against a $2.31B milestone tail — a non-incretin bet on losing fat without losing muscle. Meanwhile two House Republicans asked the FDA to stop taking China-generated trial data on trust, which is the kind of letter that turns a sourcing decision into a diligence line item.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,674.4 |
0.4% |
11.9% |
| Nasdaq 100 |
29,308.9 |
0.3% |
16.3% |
| Russell 2000 |
3,017.9 |
0.8% |
20.3% |
| Healthcare (XLV) |
174.6 |
1.3% |
12.3% |
| Biotech (XBI) |
165.7 |
1.4% |
36.4% |
| Nasdaq Biotech (NBI) |
7,285.2 |
1.3% |
27.7% |
| Clinical Trials (BBC) |
54.5 |
1.1% |
44.7% |
|
- Healthcare closed its best week since 26 June, with XBI up 1.4% and XLV up 1.3%, carried by Wednesday’s Moderna/Merck INTerpath-001 readout — the first positive Phase 3 for an individualized neoantigen therapy — which left Moderna up more than 9% on Friday alone.
- The broad tape ground higher into a losing week, S&P 500 +0.43% but down roughly 1.4% over five sessions, as Treasury yields held near long-term highs and tech gave back ground ahead of Wednesday’s July PCE print and Nvidia earnings, with Jackson Hole opening Thursday and Chair Warsh speaking Friday 28 August.
- Market data: U.S. cash close Friday, 21 August 2026.
The Big 3
|
1
|
Genentech pays $190M up front for a non-incretin obesity shot
|
- Hanmi licensed HM17321 to Genentech for $190M up front against up to $2.31B in development, regulatory and commercial milestones plus tiered royalties, granting worldwide rights excluding South Korea; Hanmi completes the ongoing Phase 1 and Genentech takes over from Phase 2.
- Why it matters: $190M against $2.31B is an 8% cash ratio — light, but so is a Phase 1 asset, and Hanmi keeps Korea plus royalties. What Roche bought is a non-incretin mechanism: HM17321 is a CRFR2-selective urocortin-2 analog, so it competes with the muscle-preservation cohort — Lilly’s bimagrumab, Regeneron’s trevogrumab, Scholar Rock’s apitegromab — rather than with Wegovy or Zepbound, and preclinical work showed it stacking with GLP-1s rather than replacing them. Read it against the $750M Oregon device plant Roche committed to last week: Basel built the delivery layer first and is now filling it. Risk is translation — a stress-axis receptor has no human efficacy record, and this is Hanmi’s second metabolic out-licence since June.
- Source: Korea Herald
- More: Seoul Economic Daily; PR
|
|
2
|
Lawmakers press FDA on China trial data after 3 deaths
|
- Reps. John Moolenaar (R-MI) and Ben Cline (R-VA) wrote to Acting FDA Commissioner Kyle Diamantas asking the agency to exclude China-generated data from INDs, NDAs and BLAs unless FDA has inspected the trial site within the prior 12 months, and to review products already approved on Chinese clinical results.
- Why it matters: Moolenaar chairs the House Select Committee on China and both men sit on the Appropriations subcommittee that funds the FDA, so this letter has a budget lever behind it. The arithmetic is what bites. China ran 32% of global trial starts in 2025 against 35% for the US, and GAO counted 46 FDA inspections of Chinese trial sites between FY2012 and March 2023. A 12-month inspection requirement at that cadence functions as exclusion, not scrutiny. The exposure sits with the China BD&L cohort — Pfizer/Innovent, Pfizer/3SBio, AstraZeneca/Sino Biopharm — where cheap, fast data was the underwriting case. None of this is law. It is the COINS Act argument acquiring a safety rationale it lacked in June.
-
Source:
Endpoints
-
More:
BioSpace; Fierce Biotech
|
| 3 | Capricor under pressure after missed deramiocel decision date |
-
Capricor’s 22 August PDUFA date for deramiocel passed with no announced FDA action, three weeks after an advisory committee voted 9–3 that the evidence did not support effectiveness in DMD cardiomyopathy, and one day after Kaos Capital demanded two board seats, a strategic alternatives committee and a cash preservation plan.
- Why it matters: Roth models roughly a three-month extension tied to the 24-month HOPE-3 upper-limb amendment the FDA agreed to review — the disclosure that took CAPR up 58% to $6.65 on 14 August. The date nobody is discounting is 30 September: deramiocel must be approved by then for the rare pediatric disease priority review voucher to be issued, and a lapsed voucher removes a nine-figure asset regardless of what the label eventually says. Kaos is pushing into exactly that gap, against $237.9M of cash at 30 June and $79.7M of first-half opex, roughly double the prior year at the G&A line. Non-deramiocel programs are paused, so there is no second story to fund.
- Source: BioSpace
- More: BioPharma Dive
|
Everything Else that broke
- Ambros and Werewolf agreed an all-stock reverse merger with a concurrent $150M private placement co-led by RA Capital and Janus Henderson, implying $500M for Ambros against $47.5M for Werewolf, whose shares rose more than 120%. — Fierce Biotech
- GC Biopharma won India and Taiwan approvals for Hunterase in Hunter syndrome. — PRNewswire
- Novo started Phase 3 testing lower maintenance doses for oral Wegovy. — BioSpace
- Bavarian Nordic pushed its Lyme vaccine trial start to 2028, delaying one of two early-stage programs it had guided into the clinic this year. — Endpoints
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
Hanmi / Genentech — exclusive worldwide licence (ex-Korea) to HM17321 for obesity; $190M upfront, up to $2.31B in milestones plus tiered royalties (Phase 1) (see The Big 3). — PRNewswire
- Ambros / Werewolf — all-stock reverse merger, combined company trading as AMBX; Ambros holders ~71.7%, placement investors ~21.5%, Werewolf ~6.8%; close expected Q1 2027 (see Everything Else). — BioSpace
- Anbogen and the University of Tokyo teamed up to study ABT-301 across multiple tumor types. — PRNewswire
VC / Private Financings
- No newly closed private financings in the window.
IPOs / Follow-Ons
- Amylyx (AMLX) closed an upsized $500.2M follow-on — 14,090,000 shares at $35.50 — days after avexitide cut Level 2/3 hypoglycemic events 55% versus placebo (p=0.000003, n=78) in Phase 3 LUCIDITY; NDA planned by year-end. Leerink, Morgan Stanley, Guggenheim and LifeSci Capital bookran. — Fierce Biotech
- Ambros / Werewolf — oversubscribed $150M private placement of common stock and pre-funded warrants, co-led by RA Capital and Janus Henderson, with Adage, ADAR1, Balyasny, Enavate Sciences, SilverArc, Sphera and Woodline participating; funds neridronate through 2028 Phase 3 topline and into 1H 2029. — BioSpace
|
Roche bought the muscle, Congress bought the pitchforks.
— BioBucks Team
|
|
|
